Medisse, a Dutch biomaterial firm, has announced that it has raised €2.6m ($3.5m) in a series B round led by life science investor IIG with participation from existing backers Omnes Capital and University of Leiden-backed BioGeneration Ventures.
In addition to the €2.6m ($3.5m), Medisse will also receive an unspecified sum in the form of innovation credit from the Dutch Ministry of Economic Affairs.
The latest round of financing will be used by Medisse to further develop its lead product, an adhesion prevention film called FlexiSurge Adhesion Barrier.
BioGeneration, which was co-founded by the Netherlands Genomics Initiative (NGI), the holding of the University of Leiden, previously invested in Medisse during 2009 in a venture round joined by Crédit Agricole Private Equity. The size of the 2009 investment was not disclosed.
Sandra de Vos, chief executive officer of Medisse, said: “We are very pleased that this investment round give us the opportunity to bring the company to the next level. With these proceeds we will perform the first clinical trial of FlexiSurge Adhesion Barrier, aiming to obtain a CE mark, but will also be used for developing other devices. The growing use of resorbable materials for soft tissue applications creates exciting opportunities for Medisse”.
